赛德罗卡林的计算工程调节其与抗高血压药物坎德沙坦的结合亲和力
Kristina Vogel1, Johanna Moeller2, Nina G Bozhanova3
1Institute for Drug Discovery, Faculty of Medicine, Leipzig University, Leipzig, Germany.
Journal of structural biology
|February 20, 2025
概括
研究人员设计了赛德罗卡林蛋白来结合康德沙坦,一种抗高血压药物. 这种蛋白质工程导致了具有显著改变结合亲和力的变体,显示了新联体结合工具的潜力.
科学领域:
- 生物化学 生物化学
- 结构生物学 结构生物学
- 蛋白质工程是指蛋白质的工程.
背景情况:
- 利波卡林蛋白因结合各种小分子而闻名.
- 西德罗卡林是一种利波卡林,与各种配体相互作用.
- 了解这些相互作用是开发有针对性的分子工具的关键.
研究的目的:
- 为了研究candesartan和siderocalin之间的相互作用.
- 阐明德沙坦-西德罗卡林结合的结构基础.
- 为了设计赛德罗卡林以调制连接体结合亲和力.
主要方法:
- 生物分子NMR实验以确定甘地沙坦与赛德罗卡林的结合.
- 整合性结构生物学结合了NMR和in silico对接来确定结合部位.
- 合理的蛋白质设计,在结合口袋中引入突变.
- 异热定位热度计,以评估工程突变的结合亲和力.
主要成果:
- 坎德沙坦被确定为小鼠和人类 siderocalin 的配体.
- 这项研究揭示了德沙坦-西德罗卡林复合体的结构洞察力.
- 改造的赛德罗卡林突变体显示结合亲和力增加了50倍,减少了5倍.
- 通过合理的蛋白质设计,成功调节了连接体结合亲和力.
结论:
- 赛德罗卡林可以在结构上进行修改,以改变对德沙坦等特定配体的结合亲和力.
- 基于结构数据的合理蛋白质设计对于调节蛋白质-连接体相互作用是有效的.
- 改造的赛德罗卡林显示出有前途的脚手架,用于开发带结合工具,如药物吸尘器.
相关概念视频
01:28Structure-Activity Relationships and Drug Design
484
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
484
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
571
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
571
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
455
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
455
01:22Dose-Response Relationship: Potency and Efficacy
4.1K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.1K
00:49Ligand Binding and Linkage
4.7K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
4.7K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
371
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
371